Skip to main content


Featured Article
“The development of a simple, easy-to-use renal support system to treat severe hyperkalemia is a major milestone in our collaboration with the US Army and Air Force,” said Vincent Capponi, MS, chief…
Strong risk factors for ACE-I/ARB discontinuation were hyperkalemia, hypotension, low bicarbonate level, and hospitalization related to acute kidney injury, researchers reported.


James J. Matera, DO, nephrologist and vice president of Medical Affairs at CentraState Medical Center in Freehold, New Jersey, recently discussed the challenges of managing hyperkalemia in patients with comorbid CKD and cardiometabolic disease, as…
Managing hyperkalemia is complex and current options are limited; new therapies may address treatment gap.
  New Treatment for Hyperkalemia Current therapy options are limited and there is an increased risk of drug–drug interactions when patients take >1 potassium increasing drug. Hyperkalemia is defined as elevated serum potassium concentrations…
Back to Top